



Seres Therapeutics to Present at Upcoming Investor Conferences

September 14, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 14, 2020-- [Seres Therapeutics, Inc.](https://www.businesswire.com/news/home/20200914005065/en/) (Nasdaq:MCRB) today announced that management will present at two upcoming investor conferences:

- **H.C. Wainwright 22nd Annual Global Investment Conference:** Seres will present a corporate overview on Wednesday, September 16 at 11:00 a.m. ET.
- **Oppenheimer Fall Healthcare Summit:** Seres will present a corporate overview on Wednesday, September 23 at 11:40 a.m. ET.

A live audio webcast of each presentation will be available under the "Investors and Media" section of Seres' website. A replay of the presentations will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq:MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent *C. difficile* infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres' SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is developing SER-401 in a Phase 1b study in patients with metastatic melanoma, SER-301 for ulcerative colitis and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200914005065/en/): <https://www.businesswire.com/news/home/20200914005065/en/>

PR

Lisa Raffensperger

lisa@tenbridgecommunications.com

IR

Carlo Tanzi, Ph.D.

ctanzi@serestherapeutics.com

Source: Seres Therapeutics, Inc.